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Dysregulated inﬂammasome activation contributes to respiratory infections and pathologic
airway inﬂammation. Through basic and translational approaches involving murine
models and human genetic epidemiology, we show here the importance of the different
inﬂammasomes in regulating inﬂammatory responses in mice and humans with cystic ﬁbrosis
(CF), a life-threatening disorder of the lungs and digestive system. While both contributing to
pathogen clearance, NLRP3 more than NLRC4 contributes to deleterious inﬂammatory
responses in CF and correlates with defective NLRC4-dependent IL-1Ra production. Disease
susceptibility in mice and microbial colonization in humans occurrs in conditions of genetic
deﬁciency of NLRC4 or IL-1Ra and can be rescued by administration of the recombinant
IL-1Ra, anakinra. These results indicate that pathogenic NLRP3 activity in CF could be
negatively regulated by IL-1Ra and provide a proof-of-concept evidence that inﬂammasomes
are potential targets to limit the pathological consequences of microbial colonization in CF.
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I
n patients with cystic ﬁbrosis (CF), a vicious cycle of airways
infection, inﬂammation and tissue damage is responsible for
the progressive decline of pulmonary function.The pulmonary
innate response in CF is dysregulated at several levels, resulting in
inefﬁcient bacterial clearance and contributing to lung disease
associated with CF1. Studies have documented an altered balance
of inﬂammatory/anti-inﬂammatory cytokines in CF2, providing
evidence that targeting speciﬁc inﬂammatory/anti-inﬂammatory
pathways is a valid therapeutic strategy in CF3,4.
Dysregulated inﬂammasome activity is a key mediator of
infections and airway inﬂammation in lung diseases5. Indeed,
NLRP3 inﬂammasome activity is involved in host response to
acute lung infections, but also during progression of several
chronic pulmonary diseases6. Assembly of these intracellular
danger sensors triggers pyroptosis and secretion of bioactive
interleukin (IL)-1b and IL-18 that are central to processes
mediating lung inﬂammation5. Both bronchial epithelial cells
(ECs)7 and haematopoietic cells8 are source of IL-1b production
in CF (between 2.8 and 32 ngml 1 in sputum from CF
children)9. IL-1 signalling triggers the activation of pathogenic
IL-17A-secreting T cells, thus critically modulating the
Th17/ regulatory T (Treg) cell balance10. This balance is
essential for the efﬁcient control of Aspergillus fumigatus
colonization and diseases in CF3, where the colonization by the
fungus is common and may lead to fungal sensitization,
bronchitis, allergic bronchopulmonary aspergillosis (ABPA)11
and FEV1 worsening12. Pathogenic Th17 cells accounted for
the inherent susceptibility to aspergillosis in CF due to an
exuberant inﬂammatory response that compromises the host’s
ability to control the infection3. Preventing NLRP3 activation and
reducing IL-1b secretion reduced infection severity in chronic
granulomatous disease13 as well as CF14. Thus, despite the key
role in host protection against the fungus14,15, the inﬂammasome/
IL-1 pathway is tightly regulated to avoid an excessive
inﬂammatory pathology16.
Similarly, despite a clear protective role for IL-1R signalling7
and NLRC4 (refs 17–19) in the innate immunity against
Pseudomonas aeruginosa, the most common pathogen in
CF, deregulated inﬂammasome signalling also aggravates
P. aeruginosa pneumonia in CF20 and non-CF21 conditions.
The fact that P. aeruginosa has adopted mechanisms to inhibit
NLRC4-mediated caspase-1 activation22 further suggests the
importance of this pathway against Gram-negative bacterial
pneumonia. Thus, the inﬂammasome may represent a potential
target to limit the pathological consequences of pulmonary
infections in CF.
In the present study, we determine the relative contribution of
different inﬂammasomes to infection and inﬂammation in CF
mice, assessed the therapeutic efﬁcacy of the recombinant IL-1R
antagonist (IL-1Ra), anakinra, and evaluated whether genetic
variations in the inﬂammasome/IL-1RI signalling could
contribute to microbial colonization and inﬂammation in human
CF. We found that NLRP3 more than NLRC4 contributes to
IL-1b-dependent inﬂammation in murine and human CF.
Pathogenic NLRP3 activity, however, is negatively regulated by
IL-1Ra, thus providing a therapeutic angle to ameliorate the
pathological consequences of microbial colonization in CF.
Results
Dysregulated inﬂammasome activity in murine CF. To evaluate
inﬂammasome activity in murine CF, we infected Cftr–/– and
C57BL/6 mice intranasally with A. fumigatus or intratracheally
with P. aeruginosa and evaluated IL-1b, IL-1a and IL-18
production, caspase-1 cleavage and expression of NLRP3 or
NLRC4 for their involvement in response to both A. fumigatus23
and P. aeruginosa17–22. We found a signiﬁcant increased
production of IL-1a and IL-1b, but not IL-18, (Fig. 1a,b) and
of the cleaved fragment of procaspase-1 (Fig. 1c) in the lungs of
Cftr–/– than C57BL/6 mice during either infection. On assessing
NLRP3 or NLRC4 gene (Fig. 1d) or protein (Fig. 1e) expression, it
was found that NLRP3 expression was robust during the ﬁrst
week of either infection with a decline thereafter. In contrast, the
expression of NLRC4 persistently increased in C57BL/6 mice
through the infection. Differently from what observed in C57BL/6
mice, NLRP3 expression persistently increased in Cftr–/– mice,
while NLRC4 expression was not sustained (Fig. 1d,e and
Supplementary Fig. 1). Conﬁrming previous ﬁndings24, AIM2
was upregulated in infection and particularly in Cftr–/– mice,
while NLRP6 was not (Supplementary Fig. 2). As
phosphorylation on Ser 533 by PKCd could be required for
NLRC4 activity25, we did immunostaining with a speciﬁc
anti-phospho (p)NLRC4 antibody to reveal that pNLRC4
expression paralleled that of NLRC4 on ECs from C57BL/6
mice but not Cftr–/– mice in which pNLRC4 could not be detected
(Fig. 1e). Immunohistochemistry of the lungs (Fig. 2a,b) and
studies done on puriﬁed cells isolated from naive lungs (Fig. 2c,d)
conﬁrmed that NLRP3 expression was higher in ECs and myeloid
(alveolar macrophages and neutrophils) cells from Cftr–/–than
C57BL/6 mice, while pNLRC4 expression was inherently lower,
particularly in Cftr–/–ECs (quantiﬁed in Supplementary Fig. 1).
These results indicate that NLRP3 and NLRC4 are differentially
regulated during infection in Cftr–/–mice compared with C57BL/6
mice, pNLRC4 activation being defective in Cftr–/–ECs.
At variance with NLRP3, whose activation by A. fumigatus
hyphal fragments has been reported23, the activation of
NLRC4 by the fungus is a novel ﬁnding that deserved further
investigation. On assessing the kinetics of protein expression of
NLRC4 and NLRP3 in RAW245.7 cells exposed to live conidia
and/or several fungal molecules, we found that NLRC4 was
maximally expressed after 2 h of exposure to decline thereafter
(Fig. 3a) at the time at which NLRP3 expression was maximally
induced (Fig. 3a); fungal polysaccharides (both a-and b-glucan)
and not other cell surface proteins or lipoproteins activated
NLRC4 (Fig. 3b), a ﬁnding suggesting that NLRC4 activation
likely occurs in concomitance with conidia germination, while
NLRP3 is activated by escaping hyphae. Activation of NLRC4 can
be mediated by cytosolic bacterial ﬂagellin26,27 and/or its cognate
recognition by TLR5 (ref. 19) and involves members of the
immune sensors NAIPs (NLR family, apoptosis inhibitory
proteins) family28. By resorting to siRNA-mediated gene
knockdown in vitro (Fig. 3c) and in vivo (Fig. 3d), we found
that the activation of NLRC4 in response to the fungus was,
similar to ﬂagellin, both TLR5- and NAIP5-dependent and
involved NF-kB signalling and not NAIP2. Both Tlr5 and Naip5
expressions failed to upregulate in the lungs of Cftr–/– as opposed
to C57BL/6 mice (Fig. 3e), a ﬁnding that may account for the
defective NLRC4 activation in CF. However, the defective NLRC4
phosphorylation in CF could be restored by blocking the
increased calcium signalling of CF airway epithelia (Fig. 3f)29, a
ﬁnding pointing to the complexity of NLRC4 activation in vivo
during infection. Indeed, despite similarity, the activation of
NLRC4 in response to A. fumigatus or P. aeruginosa appears to be
different, as A/J mice were as susceptible as NLRC4-deﬁcient
mice to A. fumigatus but not to P. aeruginosa infection
(Supplementary Fig. 3a).
NLRP3 and NLRC4 activity is non-redundant in lung infections.
To unravel the functional activity of either NLRP3 or NLRC4 in
these infection models, we assessed Nlrp3–/– or Nlrc4–/– mice for
susceptibility to either infection and inﬂammasome activity.
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Figure 1 | Dysregulated inﬂammasome activity in murine CF. C57BL/6 and Cftr/mice (n¼ 6 for all groups) were infected intranasally with live A.
fumigatus conidia or P. aeruginosa and assessed for IL-1b, IL-18 and IL-1a gene expression and cytokine production in lung homogenates of A. fumigatus-
(a) or P. aeruginosa- (b) infected mice at different days post-infection (dpi) by RT–PCR and speciﬁc ELISA; (c) Caspase-1 cleavage by immunoblotting with
speciﬁc antibodies and corresponding pixel density ratio normalized against corresponding b-actin; Nlrp3 and Nlrc4 gene expression (d) by RT–PCR in lung
tissues and protein expression (e,f) by lung immunoﬂuorescence staining with anti-NLRP3 antibody followed by anti-rabbit TRICT (e) and (f) anti-NLRC4
antibody and anti-phospho(p)NLRC4 followed by anti-rabbit TRICTand anti-hamster FITC. Cell nuclei were stained blue with DAPI. Representative images
were acquired with a high-resolution Microscopy Olympus DP71 with a  20 objective. Scale bars, 200mm, inset 50mm. Note the expression on lung
epithelium cells in the inset. Scanning densitometry was done with Image Lab 3.1.1 software. Data are representative (immunoblotting) or pooled from three
experiments and presented as mean±s.d. for all bar graphs. *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001, C57BL/6 versus Cftr/mice at different
dpi, Two-way ANOVA, Bonferroni post hoc test. For NLRP3 or NLRC4 quantiﬁcation, see Supplementary Fig. 1.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10791 ARTICLE
NATURE COMMUNICATIONS | 7:10791 | DOI: 10.1038/ncomms10791 | www.nature.com/naturecommunications 3
c
Unstimulated
Epithelial cells
Neutrophils
Macrophages
A.fumigatus Unstimulated
Epithelial cells
Flagellin
Neutrophils
Macrophages
P.aeruginosa
C5
7B
L/
6
C5
7B
L/
6
Cf
tr
–
/–
C5
7B
L/
6
Cf
tr
–
/–
Cf
tr
–
/–
DAPI NLRC4 PNLRP4
Naive
NLRC4
7 dpi
P.aeruginosa
3 dpi7 dpi3 dpi
A.fumigatusa
C5
7B
L/
6
Cf
tr
–
/–
C5
7B
L/
6
Cf
tr
–
/–
P.aeruginosa A.fumigatus
b
d
NLRP3
DAPI NLRP3
LPS+ATP
Figure 2 | Different NLRP3 and NLRC4 expression in lung cells from CF mice. C57BL/6 and Cftr/mice (n¼6 for all groups) were infected intranasally
with live A. fumigatus conidia or P. aeruginosa and assessed for (a) NLRP3 and (b) NLRC4 protein expression in the lungs and lung epithelial and myeloid
cells (magniﬁed in the insets) by immunohistochemistry. Cell nuclei were counterstained with haematoxylin. Representative images of two independent
experiments were acquired with a  20 and  60 (inset, using EVOS FL Color Imaging System) objective. Scale bar, 200mm. Immunoﬂuorescence staining
with (c) NLRP3 followed by anti-rabbit TRICT or (d) pNLRC4 and NLRC4 of epithelia cells and macrophages puriﬁed from lungs and neutrophils from the
peritoneal cavity of C57BL/6 and Cftr/ uninfected mice exposed in vitro to LPSþATP, ﬂagellin, A. fumigatus live conidia or P. aeruginosa. Cell nuclei were
counterstained blue with DAPI. Images were acquired a high-resolution Microscopy Olympus DP71 using a  100 objective. Scale bar, 12.5 mm. For number
of cells with positive NLRP3 or NLRC4 expression quantiﬁcation, see Supplementary Fig. 1.
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Nlrp3–/– mice showed increased resistance to either infection, as
revealed by the reduced fungal or bacterial load (Fig. 4a), IL-1b
production (Fig. 4b) and lung inﬂammatory cell recruitment
(Fig. 2c). Only when infected with a high number of Aspergillus
conidia were Nlrp3–/– mice more susceptible and unable to restrict
fungal growth and inﬂammatory pathology (Supplementary
Fig. 4). In contrast, Nlrc4–/– mice were less efﬁcient in
restraining either the fungal or bacterial growth (Fig. 4a), despite
elevated IL-1b production (Fig. 4b). Moreover, these mice were
unable to control the local inﬂammatory cell recruitment (Fig. 4c)
and succumbed to the P. aeruginosa infection (Fig. 4d).
In addition, blocking Nlrp3 with siRNA increased resistance to
Aspergillus infection in both C57BL/6 and Cftr–/– mice, as revealed
by decreased lung colony-forming units (CFUs; Fig. 4e) and
pathology as well as decreased positive staining for terminal
deoxynucleotidyl transferase-mediated deoxyuridine triphosphate
nick-end labelling (TUNEL; Fig. 4f), a marker of both
apoptotic and pyropoptotic cell death30. In contrast, blocking Nlrc4
did not affect the susceptibility of C57BL/6 or Cftr–/– mice
(Fig. 4e,f). Similar results were obtained with P. aeruginosa
infection (Supplementary Fig. 5). These data suggest that
NLRP3 and NLRC4, despite having overlapping functions, may
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Figure 3 | The TLR5/NAIP5 pathway of NLRC4 activation is defective in murine CF. RAW 247.3 macrophages were exposed to (a) A. fumigatus live
conidia before the assessment for NLRP3 or NLRC4 protein expression at different times by immunoblotting with speciﬁc antibodies or to (b) various
fungal antigens for 2 h at 37 C before NLRC4 protein expression by western blotting. (c) Cells were pretreated with speciﬁc siRNA for Tlr5, Naip2, Naip5 or
scrambled siRNA (siScram) or the NF-kB inhibitor SN50 (100mM), exposed to Aspergillus conidia or ﬂagellin for 2 h at 37 C and assessed for NLRC4
protein expression by western blotting. All immunoblots were normalized against the corresponding b-actin. (d) C57BL/6 mice were given siRNA
intranasally twice, 2 days before and 3 days after the infection before the assessment of NLRC4 protein expression at 4 dpi. (e) Tlr5, Naip2 and Naip5
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at the ratio cells:microbes (1:1) in the presence of EDTA at 37 C. The expression of pNLRC4 was normalized against the corresponding b-actin. Data
pooled from three experiments and presented as mean±s.d. for all bar graphs. *Po0.05, ***Po0.001, ****Po0.0001, None versus infected mice, Two-
way ANOVA, Bonferroni post hoc test.
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have a different role in these lung infections whereby NLRP3
may contribute to pathogenic inﬂammation in the relative
absence of NLRC4. As such, these results are consistent with the
high or low susceptibility to bacterial or fungal pneumonia
observed in mice with a high or low inﬂammasome activity,
such as Il1r8–/– and Il1r1–/– mice, respectively14,21,31,32 in
which we found that NLRP3 expression was more robust in the
former than in the latter (Supplementary Fig. 6). Thus,
IL-1RI signalling leading to NLRP3 activation may promote
deleterious inﬂammation in response to A. fumigatus and
P. aeruginosa in CF.
NLRC4 induces IL-1Ra that dampens NLRP3 activity. The
protective action of NLRC4 in Gram-negative bacterial
pneumonia is mostly carried out in cooperation with NLRP3 to
drive robust IL-1b signalling21,33. However, the precise
mechanism(s) by which NLRC4 mediates its effects in the lung
remains to be determined. IL-1Ra is a potent suppressor of
inﬂammasome activity34. Although most intracellular IL-1Ra
remains in the cytoplasm of cells, some isoforms may be released
from airways ECs in some conditions and may act as extracellular
receptor antagonists of IL-1RI (ref. 35). We have evidence that
NLRC4 activation in response to Candida albicans resulted in a
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experiments were acquired using EVOS FL Color Imaging System with a 40 objective for histology (Scale bar, 100mm) and a high-resolution Microscopy
Olympus DP71 using a  20 objective for TUNEL (Scale bar, 50mm). Data pooled from three experiments and presented as mean±s.d. for all bar graphs.
*Po0.05, **Po0.01, ***Po0.001, ****Po0.0001, C57BL/6 versus Nlrp3 / , Nlrc4 /or Cftr/mice at different dpi (a,b) or untreated (none) versus
siRNA treated mice (e), Two-way (a,b) and One-way ANOVA (e) Bonferroni post hoc test.
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sustained production of IL-1Ra capable of restraining NLRP3
activity36. Should this mechanism be operative in the lung, this
would suggest that NLRP3 expression is sustained in Nlrc4–/– as
well as Il1ra–/– mice and that NLRC4 contributes to IL-1Ra
production in either bacterial or fungal pneumonia. We observed
a robust Nlrp3 gene (Fig. 5a) and protein (Fig. 5b) expression in
Nlrc4–/– or Il1ra–/– (Fig. 6m) infected mice as well as the major
contribution of NLRC4 to IL-1Ra production. Indeed, the levels
of IL-1Ra were sustained in vitro (Fig. 5c) and through the course
of either infection in vivo (Fig. 5d) in C57BL/6 but not Cftr–/–
mice and NLRC4, more than NLRP3, contributed to this
sustained production (Fig. 5d). Accordingly, IL-1Ra was
deﬁcient upon blocking TLR5 and NAIP5, both in vitro and
in vivo (Supplementary Fig. 7a,b), as well as in A/J mice
(Supplementary Fig. 3b) and was associated with increased IL-1b
production and inﬂammatory responses. The opposing ﬁndings
observed with ﬂagellin (Supplementary Fig. 7a,b), further suggest
the protective role of the TLR5/NLRC4 axis in infection.
Altogether, these results suggest that NLRC4 and IL-1Ra
deﬁciencies may contribute to NLRP3-mediated pathogenic
inﬂammation in CF and that limiting NLRP3 via IL-1Ra could
be of beneﬁt in CF mice.
Anakinra protects from infections and inﬂammation. These
observations prompted us to investigate whether anakinra would
ameliorate lung inﬂammatory pathology in CF. We treated
C57BL/6 and Cftr–/– mice infected with either Aspergillus or
Pseudomonas with 10mg kg 1 anakinra, a dose known to mimic
human therapeutic dosages and to be pharmacologically active in
mice13,34. Anakinra signiﬁcantly increased survival of Cftr–/– mice
to P. aeruginosa infection (Fig. 6a) while reducing bacterial
burden (Fig. 6b), neutrophil recruitment and lung damage
(Fig. 6c). In addition, anakinra reduced caspase-1 cleavage
(Fig. 6d), IL-1b production (Fig. 6e) and lung NLRP3
expression (Fig. 6f). Similar results were obtained in
Aspergillus-infected Cftr–/–mice (Fig. 6g–k). Of interest,
anakinra greatly increased the resistance to A. fumigatus
infection (Fig. 6l), while decreasing NLRP3 expression
(Fig. 6m), of the highly susceptible Il1ra–/– mice.
Mechanistically, regulation of NLRP3 expression by anakinra
occurs at posttranslational level via the ubiquitin proteasome
system (Supplementary Fig. 8), a degradation pathway known to
regulate NLRP3 half life37. Altogether, these results indicate that
by impairing neutrophil recruitment, anakinra may ameliorate
lung pathology, without adversely affecting pathogen clearance.
Of great interest, anakinra treatment was apparently more potent
than the inhibition of IL-1b by a neutralizing antibody
(Supplementary Fig. 9), a ﬁnding suggesting that the beneﬁcial
effect of anakinra may go beyond inﬂammasome inhibition.
In this regard, autophagy is a mechanism involved in the
intracellular defense against both A. fumigatus38,39 and
P. aeruginosa40, is defective in CF41 and is induced by
anakinra13. We monitored the effects of anakinra on autophagy
induction in response to live conidia or bacteria in lung
macrophages puriﬁed from C57BL/6 or Cftr–/–mice. Anakinra
restored the defective autophagy in CF cells, as seen by LC3
immunoﬂuorescence (Fig. 7a) and immunoblotting (Fig. 7b).
Through autophagy, anakinra also increased the microbicidal
activity of macrophages (Fig. 7c). Autophagy is activated by ROS
and inhibited by chloroquine, a lysosomotropic agent that
inhibits the fusion of autophagosome with lysosome and
lysosomal protein degradation42. Accordingly, the anakinra
activity was inhibited by chloroquine and the NADPH oxidase
inhibitor diphenyleneiodonium DPI43, thus indicating that
anakinra activates the autophagy/lysosomal degradation
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Figure 5 | NLRC4 produces IL-1Ra. C57BL/6, Nlrp3 / , Nlrc4 / and
Cftr/ mice (n¼ 6 for all groups) were infected intranasally with live
A. fumigatus conidia or P. aeruginosa. NLRP3 gene (a) and protein
(b) expression by RT–PCR or immunoﬂuorescence staining (anti-NLRP3
antibody followed by anti-goat TRICTsecondary antibody) of lungs at 7 dpi.
Cell nuclei were stained blue with DAPI. Representative images of two
independent experiments were acquired with a high-resolution Microscopy
Olympus DP71 using a  20 objective. Scale bar, 200mm, inset 50mm.
IL-1Ra production (quantiﬁed by speciﬁc ELISA) in (c) supernatants of
puriﬁed lung epithelial cells exposed to the different stimuli, with and
without 2mM of EDTA for 6 h at 37 C and (d) lung homogenates at
different dpi. Data are representative (immunoﬂuorescence) or pooled from
three experiments and presented as mean±s.d. for all bar graphs.
*Po0.05, **Po0.01, ***Po0.001, ****Po0.0001, C57BL/6 versus
Nlrp3 / , Nlrc4 / and Cftr/ mice at different dpi. Two-way ANOVA
Bonferroni post hoc test. For NLRP3 quantiﬁcation, see Supplementary Fig. 1.
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pathway. However, the anakinra activity was also inhibited by
lactacystin, a known inhibitor of the proteasomal degradation
pathway44. Thus, the activity of anakinra seems to rely on both
the autophagy and the proteasome system, two cooperative and
complementary degradation pathways45. Consistently, anakinra
modiﬁed the intracellular routing of live conidia on phagocytosis.
We followed the intracellular localization of green ﬂuorescent
protein (GFP)-conidia on lung macrophages puriﬁed from
C57BL/6 and Cftr–/–mice by determining the colocalization and
quantifying the degree of overlap with either the lysosomal-
associated membrane protein 1 (LAMP1) or the 20S proteasome
of protein degradation. Figure 7d shows that phagocytosed GFP-
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Figure 6 | Anakinra protects Cftr/mice from infections and NLRP3 inﬂammation. C57BL/6 and Cftr/ mice (n¼ 6 for all groups) were infected
intranasally with live A. fumigatus conidia or P. aeruginosa and treated with anakinra (100mg kg 1 per day) throughout the infection. (a,g) Survival, (b,h)
microbial growth (log CFU, mean±s.d.), (c,i) lung histology (periodic acid-Schiff staining) and reduced deposition of DNA on lung parenchyma cells by
TUNEL; (d) caspase-1 cleavage by immunoblotting with speciﬁc antibodies (scanning densitometry was done with Image Lab 3.1.1 software. Representative
of three independent experiments and corresponding pixel density ratio normalized against actin); (e,j) IL-1b levels in lung homogenates; NLRP3 protein
expression by immunoﬂuorescence staining (f) and immunoblotting (k) of lungs of anakinra-treated mice. Assays were done at 7 dpi. (l) Fungal growth
(log CFU, mean±s.d.) and (m) lung histology (periodic acid-Schiff staining and NLRP3 immunoﬂuorescence staining in the inset) of A. fumigatus-infected
and anakinra-treated Il1ra / mice. Representative images of two independent experiments were acquired using EVOS FL Color Imaging System
with a 40 objective for histology (Scale bar, 100 mm) and a high-resolution Microscopy Olympus DP71 using a  20 objective for TUNEL and
immunoﬂuorescent staining (Scale bar, 200mm, inset 50mm). Data pooled from three experiments and presented as mean±s.d. for all bar graphs.
*Po0.05, **Po0.01, ***Po0.001, anakinra treated versus untreated mice (none), One-way ANOVA (b,h), Two-way ANOVA (e,j) Bonferroni post hoc test
and two-sides Student’s t-test. (l) For NLRP3 quantiﬁcation, see Supplementary Fig. 1.
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conidia rapidly (at 5min) colocalized with LAMP1 in either type
of macrophages. Colocalization was increased by anakinra.
However, at 45min, anakinra reduced the colocalization with
LAMP1, while it increased the colocalization with the 20S
proteasome (Fig. 7d). Consistent with the regulation of NLRP3
expression (Supplementary Fig. 8), the proteosomal degradation
pathway in RAW cells (Fig. 7e) and in CF-HBE cells (Fig. 7f) was
promoted by anakinra. Thus, anakinra not only controls the
intracellular routing of pathogens upon phagocytosis through
autophagy, but also reduces and NLRP3’s half-life possibly via the
proteasome system, and therefore controls both pathogen
clearance and inﬂammation.
Anakinra inhibits inﬂammasome activation in human CF. To
assess whether anakinra would also be able to inhibit NLRP3
activation in human CF bronchial ECs (CF-HBE), we evaluated
NLRP3 and NLRC4 protein levels in primary HBE from non-CF
patients and CF patients46 after 4 h of exposure to A. fumigatus,
P. aeruginosa and/or anakinra. NLRP3, but not NLRC4,
expression was increased in the presence of a pathogen in CF-
HBE compared to control cells. Anakinra reduced the intensity of
NLRP3 staining (Fig. 8a) and, concurrently, IL-1b production
(Fig. 8b) without signiﬁcantly affecting NLRC4 staining. Of
interest, the levels of IL-1Ra were signiﬁcantly lower in CF-HBE
(Fig. 8c) and CF expectorates (Fig. 8d) as compared with controls,
a ﬁnding indicating a defective NLRC4 activity in human CF.
NLRC4 and IL1RN polymorphisms affect microbial colonization.
To assess whether genetic variants in the inﬂammasome/IL-1RI
signalling pathway, and particularly genetic NLRC4 deﬁciency, are
risk factors for speciﬁc microbial colonization in CF, we evaluated
nine gene variants (four in NLRC4, two in NLRP3, one in IL1B and
one in IL1RN) in 284 CF patients (Supplementary Table 1). These
variants were successfully genotyped in the samples (genotyping
rate 94.3–100%), without displaying any deviation from the Hardy–
Weinberg Equilibrium (Supplementary Table 2). Linkage dis-
equilibrium (LD) analyses of the single-nucleotide polymorphisms
(SNPs) in NLRC4 and NLRP3 (r2¼ 0.03), failed to reveal the pre-
sence of signiﬁcant LD blocks (Supplementary Fig. 10). For A.
fumigatus colonization, signiﬁcant associations were found for
NLRC4 ACTT haplotype (odds ratio (OR)¼ 2.930, P¼ 0.025) and
for NLRC4 rs212704 G/G genotype (OR¼ 0.303, P¼ 0.030;
Table 1). To establish the functional effects of these SNPs we
evaluated NLRC4 expression in lung expectorates from genotyped
CF patients. The AA genotype at rs212704, the CC genotype at
rs455060, the TT genotype at the rs7562653 and the TT genotype at
rs385076 show a reduction in NLRC4 expression level compared
with other genotypes (Fig. 8e). Therefore, genetic NLRC4 deﬁ-
ciency, but not NLRC4 sufﬁciency (rs212704), predisposes CF
patients to Aspergillus colonization. No signiﬁcant associations were
found between Aspergillus colonization and the other genetic var-
iants (Supplementary Tables 3–6) and no signiﬁcant gene–gene
interaction was detected (Supplementary Table 7). For P. aerugi-
nosa colonization, no signiﬁcant association was detected either at
haplotype and single marker level (allele and genotype) tests
(Supplementary Tables 8–11). However, on performing the gen-
eralized-multifactor dimensionality reduction analysis, two sig-
niﬁcant gene–gene interaction models (Table 1), involving NLRC4
and IL1RN gene variants, signiﬁcantly increased the risk of Pseu-
domonas colonization (NLRC4 rs212704 IL1RN VNTR,
OR¼ 3.018, Sign test P¼ 0.001; NLRC4 rs212704NLRC4
rs385076 IL1RN VNTR, OR¼ 4.212, Sign test P¼ 0.001; Fig. 8f).
These data indicate that genetic deﬁciency of NLRC4, either alone
or in combination with IL-1R1N, could be a risk factor for speciﬁc
microbial colonization in the lungs of patients with CF.
Discussion
The present study shows that the interplay between NLRP3 and
NLRC4 governs host innate immune response and inﬂammation
to colonizing microbes in murine and human CF. As infections
have a negative impact on pulmonary functions in CF47,
categorizing microbial colonization versus infection may help
stratify CF patients for preventive treatment. NLRP3 activation
contributed to neutrophil recruitment in both A. fumigatus and
P. aeruginosa infections, a ﬁnding conﬁrming the contribution of
NLRP3, either alone14,20 or in association with other cytoplasmic
sensors24, to the inﬂammatory responses in the lung. However,
inﬂammation and tissue damage were greatly reduced in Nlrp3–/–
infected mice and NLRP3-dependent neutrophil inﬁltration and
proinﬂammatory cytokine responses were associated with disease
severity in conditions of unrestrained NLRP3 activity, such as in
highly susceptible Il1r8–/–, Il1ra–/– or Nlrc4–/– mice. NLRP3
activity was instead defective in Il1r1–/– mice, in which the
attenuated IL-1b production was concomitant with a reduced
disease severity during infections. While it is conceivable that the
net functional activity of NLRP3 in the lung is also contingent, at
least for A. fumigatus, on the fungal load (Supplementary Fig. 4),
the fungal strain and route of infection15,24, our results indicate
that the NLRP3 inﬂammasome is tightly regulated to avoid its
aberrant activation6.
Indeed, NLRP3 was signiﬁcantly increased in murine and
human CF cells and its inhibition ameliorated inﬂammatory
pathology in murine experimental infections and attenuated
IL-1b production in human CF cells. The increased NLRP3
inﬂammatory response could be intrinsic to cells lacking CFTR due
to the mitochondrial Ca2þ perturbation20. However, we found
that NLRP3 activity could also be counteracted by the sustained
production of IL-1Ra, to which NLRC4 greatly contributed. Several
lines of evidence suggest an important function of NLRC4 for
caspase-1 activation in response to intracellular as well as
extracellular Gram-negative bacterial infection of the
lung17,18,21,27. Activation of NLRC4 can be mediated by cytosolic
bacterial ﬂagellin26,27 and/or its cognate recognition by TLR5
(ref. 19), or be ﬂagellin-independent through the type III secretion
system18,48. In addition, activation of NLRC4 occurs after the
assembly with members of the immune sensors NAIPs family28
that control ligand-dependent oligomerization of NLRC4 and may
involve phosphorylation of the serine residue 553 by PKCd
(ref. 25). In pulmonary P. aeruginosa infection, NLRC4 activation
occurs through the participation of members of the NAIPs
family28 via an intact type III secretion system that mediates the
cytosolic translocation of ﬂagellin or PrgJ-like rod proteins18,22,49.
In aspergillosis, we found that NLRC4 activation occurs through
the TLR5/NAIP5/NF-kB-dependent pathway. Because both Tlr5
and Naip5 expressions failed to upregulate in the lungs of CF mice,
decreased expression of TLR5 was observed in CF macrophages50,
and TLR5 gene variations inﬂuenced CF lung function51, these
ﬁndings may account for the defective NLRC4 activation in CF.
However, NLRC4 activation was also sensitive to calcium
signalling. How the TLR5/NAIP5 and calcium signalling
pathway speciﬁcally interact in NLRC4 activation and how it is
affected by CFTR deﬁciency is unknown. However, it is intriguing
that a Ca2þ ﬂux occurs downstream TLR5 activation52 and
tyrosine phosphorylation of PKCd is calcium dependent53.
Whatever the case, the increased [Ca2þ ]i and Ca2þ -dependent
signalling, known to promote NLRP3 activation54, actually
restrains NLRC4 activation, a ﬁnding further pointing to the
different regulation of either inﬂammasome in Aspergillus
infection.
The defective NLRC4 activity observed in murine and human
CF is a novel ﬁnding that may open new perspectives in the
pathogenesis and therapy of inﬂammatory lung diseases in CF.
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Nlrc4–/– mice produced more IL-1b and developed a more severe
inﬂammatory response and tissue damage in both infections,
despite their ability to restrict the pathogen growth, as already
shown21. Disease susceptibility was dependent on NLRP3-driven
inﬂammation, suggesting that NLRC4 may act as a negative
regulator of NLRP3. Although the role of CFTR in myeloid cells is
being appreciated55, we have found that defective NLRC4
activation in murine and human CF ECs resulted in an
impaired production of IL-1Ra, which has the capacity to
inhibit NLRP3 inﬂammasome activation. Although typically
secreted by monocytes and PMNs, bioactive IL-1Ra isoforms
could also be released from ECs in some conditions and may
represent a mechanism by which IL-1 bioactivity is locally
modulated35. However, as NLRC4 also regulates IL-18
production56, the low levels of IL-18 (this paper) and,
consequently, of IFN-g3 observed in CF could represent an
additional mechanism by which NLRC4 regulates infections and
inﬂammation in the respiratory tract.
Altogether, these ﬁndings point to the many similarities but
also striking differences between NLRP3 and NLRC4 and add a
layer of speciﬁcity to the innate immune response against the
different pathogens that could be therapeutically exploited.
A recent Cochrane review57 has provided no deﬁnitive
conclusions on the safety and efﬁcacy of the various
immunosuppressive, anti-inﬂammatory drugs among patients
with CF. Different from the anti-tumour necrosis factor
approaches, associated with infectious complications, treatment
with IL-1Ra has demonstrated an excellent safety proﬁle, with no
adverse reactions or superinfections with long-term treatment58.
Anakinra decreased neutrophil inﬁltration, ameliorated tissue
damage and inﬂammation against both A. fumigatus and
P. aeruginosa infection, while decreasing NLRP3 activity in
both murine and human CF. This occurred through the
lysosomal pathway, through which pathogen clearance was
promoted, and the ubiquitin/proteasomal degradation pathway
through which NLRP3 activity was speciﬁcally controlled. Thus,
anakinra appears to fulﬁll the requirement of an ideal
immunomodulatory molecule capable of exerting pathogen
control with minimum pathology. In addition, a recent report
suggests that IL-1a, which is released when ECs become necrotic
due to hypoxia, also signiﬁcantly contributes to neutrophilic
inﬁltration in the lungs of CF mice and this could be ameliorated
by the use of anakinra59. IL-1a can induce IL-1b and results in an
autoinﬂammatory loop that is also dependent on caspase-1
activation. Therefore, since anakinra will block both the effects of
IL-1b and IL-1a and in addition has impact on several key
inﬂammatory mechanisms such as NLRP3 inﬂammasome
activation and autophagy, anakinra might be beneﬁcial in CF
by targeting multiple pathogenic mechanisms.
Finally, in line with the functional experimental data, the
genetic analysis supports the role of NLRC4 in determining
the state of microbial colonization of CF patients. In particular,
the signiﬁcant association of the intronic SNP rs212704 in
NLRC4, leading to defective NLRC4 expression, with A. fumigatus
colonization in CF patients suggests the presence of an
‘immunogenetic’ background predisposing CF patients to speciﬁc
microbial colonization. Moreover, consistent with the different
activation of NLRC4 by Aspergillus or Pseudomonas, the
gene–gene interaction analyses clearly showed that NLRC4 SNPs
act synergistically with IL1RN VNTR60 to increase the
susceptibility to P. aeruginosa colonization. Notably, the
opposite (protective) allele IL1RN*2 has been previously
associated with higher IL-1Ra and lower IL-1b release60.
In conclusion, our study shows that the elucidation of
pathogenic, inﬂammasome-dependent mechanisms at the mole-
cular level may help the development of novel strategies for patient
stratiﬁcation and personalized tailored approaches in human CF.
Methods
General experimental approaches. No samples, mice or data points were
excluded from the reported analyses. No randomization procedure was
implemented, however, mice were randomly assigned to group allocation at the
time of purchase to minimize any potential bias. No blinding was applied on
harvesting cells after the treatments.
Mice. Six to 8-week female mice were used in all experiments. C57BL/6 mice were
purchased from Charles River (Calco, Italy) and genetically engineered homozygote
Cftr–/– (Cftr tm1Unc) mice gut-corrected on C57BL/6 background61 were bred under
speciﬁc pathogen-free conditions at the Animal Facility of San Raffaele Hospital,
Milan, Italy. Nlrp3–/–, Nlrc4–/– and Il1ra–/– mice on the C57BL/6 background were
bred under speciﬁc pathogen-free conditions at the Animal Facility of the University
of Perugia, Perugia, Italy. Breeding pairs of Nlrc4–/–were obtained from Genetech
(South San Francisco, CA, USA). Breeding pairs of Nlrp3–/– were obtained from
Dr Alessandra Mortellaro (Singapore Immunology Network, Agency of Science,
Technology and Research, Biopolis, Singapore). Il1r8–/–and Il1r1–/–mice on the
C57BL/6 background were bred under speciﬁc pathogen-free conditions at the
Animal Facility at the Humanitas Hospital, Milan, Italy.
Infections and treatments. Viable conidia (95%) of A. fumigatus (AF293) were
obtained by growth on Sabouraud dextrose agar (Difco Laboratories, Detroit, MI,
USA) supplemented with chloramphenicol for 5 days at room temperature. Mice
were anaesthetized by intraperitoneal injection of 2.5% avertin (Sigma Chemical
Co, St. Louis, MO) before intranasal instillation of a suspension of 2 107 resting
conidia per 20 ml saline and/or ﬂagellin (Sigma-Aldrich) at 100 ng per 20 ml saline.
For P. aeruginosa infection, clinical P. aeruginosa strain, isolated from a patient,
was obtained from the Diagnostic Unit of Microbiology from the University of
Perugia. The bacteria were grown for 3 h to reach exponential phase. Next, the
bacteria were pelleted by centrifugation (2,700g, 15min), washed twice with sterile
PBS and the OD of the bacterial suspension was adjusted by spectrophotometry at
600 nm. The intended number of cfu was extrapolated from a standard growth
curve. Appropriate dilutions with sterile PBS were made to prepare the inoculum
before intranasal instillation of 3 107 CFU per mice. Mice were monitored for
fungal growth and histology. Microbial growth was expressed as log10 CFU per
Figure 7 | Anakinra promotes the autophagy and proteasomal degradation pathway. (a) Autophagy on puriﬁed lung macrophages from C57BL/6 or
Cftr/mice stimulated with Aspergillus conidia or P. aeruginosa in the presence of 10mgml 1 anakinra and incubated with anti-LC3 antibody followed by
PE secondary antibody. Representative images (original magniﬁcation, 40) are shown. DAPI was used to detect nuclei. Numbers refer to % positive cells.
Scale bar, 12.5 mm. (b) Density of bands from western blots of LC3b-I and II in homogenates of lungs of naive, Aspergillus- or Pseudomonas-infected
untreated (none), or infected and anakinra-treated mice at 7 dpi. (c) Conidiocidal activity of RAW264.7 cells pretreated with DPI, 3-MA, lactacystin or
chloroquine before the exposure to live A. fumigatus resting conidia for 2 h in the presence of anakinra. Conidiocidal activity refers to inhibition of CFUs
(expressed as mean percentage±s.d. for all bar graphs, data pooled from three experiments). Each treatment had no effects on fungal growth in the
absence of effector cells. *Po0.05, ****Po0.0001, pretreated versus anakinra 10mgml 1 only, one-way ANOVA, Bonferroni post hoc test.
(d) Immunoﬂuorescence imaging of puriﬁed alveolar macrophages from lungs of C57BL/6 or Cftr/mice after in vitro exposure to GFP-conidia at 37 C
for 2 h and chasing for 15 and 45min. Formaldehyde-ﬁxed cells were incubated with primary antibodies against Lamp1 or 20S followed by secondary anti-
rabbit IgG–TRITC antibody. Nuclei were counterstained with DAPI. Images were acquired using EVOS FL Color Imaging System with 40 objective. Shown
are merged images of cells (a single cell is magniﬁed in the inset) pulsed with GFP-conidia and red-stained for each compartment. Shown are
representative data from three independent experiments.(e,f) RAW 247.3 (e) and HBE (f) cells from control or CF patients were stimulated with Aspergillus
conidia in the presence of anakinra for 4 h and the amount of pmols of proteolytic activity was analysed with the proteasome activity assay kit (Abcam)
Shown in the insets the relative slope with error bars representing the mean±s.d. *Po0.05, ***Po0.001, None versus anakinra, Student’s t-test.
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organ, mean±s.d. For histology, parafﬁn-embedded sections (3–4 mm) were
stained with Periodic acid-Schiff (PAS). BAL ﬂuid collection was done as descri-
bed3. Differentials were determined by examination of cytocentrifuge slides after
May Grunwald Giemsa staining (Sigma-Aldrich). Histology sections and cytospin
preparations were observed using EVOS FL Color Imaging System (Fisher
Scientiﬁc) and images were captured using high-sensitivity monochrome Sony
ICX285AL CCD camera. Mice were treated intraperitoneally, from the day of
infection until the end of the experiment, with anakinra 10mg kg 1, daily, given
the half-life of IL-1Ra of 6–8 h (ref. 62) or with 10 mg per mouse anti-IL1b antibody
(RD systems, clone 30311) intranasally at the day of the infection and continuing
every other day throughout the experiment.
Cell preparation and culture. RAW264.7 cells (ATCC) were grown in RPMI 1640
medium supplemented with 1% Pen–Strep, 10mM L-glutamine, 1% HEPES
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(Lonza, Basel Switzerland), 40mgml 1 gentamicin (Fisiopharma), 0,1%
b-mercaptoethanol (Gibco, Thermo Scientiﬁc) and 10% FCS (Invitrogen,
Life Technologies) at 37 C in 5% CO2. Lung ECs were isolated from total lung cells
by washing and resuspending lung fragments in prewarmed HBSS with
0.1mgml 1 DNase I and incubated at 37 C for 1 h to allow enzymatic digestion.
After blocking enzymatic activity with the addition of FBS the residues were
magnetically separated with magnegtic beads (Miltenyi Biotech). Macrophages
were isolated after 2 h plastic adherence at 37 C. Neutrophils were positively
selected with magnetic beads (Miltenyi Biotech) from the peritoneal cavity of
uninfected mice 8 h after the intraperitoneal injection of 1ml endotoxin-free 10%
thioglycollate solution. Cells were plated in an 8-well culture slide or 12-well
culture plate and stimulated for 4 h at 37 C with 10mgml 1 ﬂagellin, 10mgml 1
LPS (Sigma-Aldrich), live Aspergillus conidia or P. aeruginosa at the ratio cells:-
microbes (1:1) or fungal antigens (10 mgml 1)63. ATP (Sigma-Aldrich), 2mM,
was added 30min before the end of the experiment. EDTA 2mM was added at the
same time as the infection. Cells were then ﬁxed with 4% paraformaldyde and
stained with anti-NLRP3 (Cat. Number ab4207, Abcam) followed by goat
anti-mouse Alexa Fluor 555 (Clone Poly4053, Biolegend) or anti-pNLRC4
(Genetech) followed by polyclonal anti-hamster FITC (Sigma-Aldrich) and Ipaf
(Cat. Number 06-1125, Millipore) followed by polyclonal anti-rabbit TRITC
(Sigma-Aldrich). All primary antibodies were used at the concentration of
0.5 mgml 1 and secondary TRICT or FITC coniugated antibodies at 1 mgml 1.
Images were acquired using a ﬂuorescence microscope (BX51 Olympus) with a
 20 objective and the analySIS image processing software (Olympus).
40-6-Diamino-2-phenylindole (DAPI, Molecular Probes, Invitrogen Srl., Milan,
Italy) was used to counterstain tissues and to detect nuclei. A minimum of 100 cells
were counted per group and the percentages indicating the number of cells
showing either NLRP3 or PNLRC4 localization was obtained. Cell extracts were
analysed by western blotting and supernatants for IL-1Ra content by ELISA. For
NLRP3 half-life experiments, cycloheximide, 40 mgml 1, treatment was carried
out, with or without 10mgml 1 anakinra, at various time points in 0% FBS
medium, on RAW264.7 cells stimulated with LPS (10 mgml 1) for its ability to
increase NLRP3 half-life37 and/or MG132 (20 mgml 1) or leupeptin (20 mgml 1).
Cell lysates were assessed for NLRP3 protein expression by western blotting.
siRNA design and delivery. The Integrated DNA technologies-pool duplexes of
predesigned siRNA (Nlrp3, dupex name: MMC.RNAI.N010552.12.1, Nlrc4 dupex
name: MMC.RNAI.N010552.12.1, Tlr5 duplex name: (MMC.RNAI.N016928.12.1),
Naip2 duplex name: (MMC.RNAI.N010872.12.1) and Naip5 duplex name:
(MMC.RNAI.N010870.12.1) were purchased from IDT (TEMA ricerca, Italy). For
in vivo studies, each mouse was lightly anaesthetized by inhaled diethyl ether, then
given intranasal administration of unmodiﬁed siRNA (10mg kg 1) or equivalent
doses of nonspeciﬁc control siRNA duplex in a volume of 20 ml of duplex buffer
(IDT, Tema ricerca). It is known that lung-speciﬁc siRNA delivery can be achieved
by intranasal administration without the need for viral vectors or transfection
agents in vivo3. Intranasal siRNA was given twice 2 days before infection or 3 days
after infection. For in vitro studies, speciﬁc predesigned siRNA was transfected into
RAW264.7 macrophages using TransIT-TKO Transfection Reagent (Mirus) and
incubated for 24 h (as indicated by preliminary experiments performed at 12, 24 or
48 h) at 37 C in 5% CO2. The efﬁciency of gene silencing was assessed by RT–PCR
at 48 h in unstimulated cells (Supplementary Fig. 11). Cells were pretreated with
the 100mM NF-kB inhibitor, SN50 (Calbiochem) for 30min.
Immunoﬂuorescence and immunohistochemistry. The lung was removed and
ﬁxed in 10% phosphate-buffered formalin, embedded in parafﬁn and sectioned at
5 mm. Sections were then rehydrated and after antigen retrieval in citrate buffer
(10mM, pH6), sections were ﬁxed in 2% formaldehyde for 40min at room tem-
perature and permeabilized in a blocking buffer containing 5% FBS, 3% BSA, and
0.5% Triton X-100 in PBS. The slides were then incubated at 4 C with primary
antibodies anti-NLRP3 (Cat. Number ab4207, Abcam) or anti-pNLRC4 (Genetech)
and anti-NLRC4 (Cat. Number 06-1125, Millipore). After extensive washing with
PBS, the slides were then incubated at room temperature for 60min with secondary
antibodies, for NLRP3 goat anti-mouse Alexa Fluor 555 (Clone Poly4053
Biolegend) for pNLRC4 polyclonal anti-hamster FITC (Sigma-Aldrich) and for
NLRP4, anti-rabbit TRITC (Sigma-Aldrich). Nuclei were counterstained with
DAPI. Corresponding average immunoﬂuorescence intensities of NLRP3 and
NLRC4 were calculated by using Image J software calculated on 142 142
pixel area64. For immunohistochemistry, sections were incubated overnight with
anti-NLRP3 (Abcam) or polyclonal NLRC4 (Millipore) followed by biotinylated
secondary antibodies. Cells were counterstained with hematoxylin or DAPI to
detect nuclei. For intracellular routing of conidia, puriﬁed alveolar macrophages
were plated in complete medium into chambered coverglass (Lab-Tek/Nunc;
Thermo Scientiﬁc) in a temperature-regulated environmental chamber and
exposed to GFP-conidia (at a 1:4 cell/conidia ratio), in serum free RPMI-1640
medium and time chased at 45min. After washout, cells were ﬁxed, permeabilized
and incubated at 4 C with primary antibodies produced in rabbit against LAMP1
or 20S (Sigma-Aldrich) as described65. After extensive washing with PBS, the cells
were incubated at room temperature for 60min with 1:400 secondary anti-rabbit
IgG–TRITC antibody (Sigma-Aldrich). All images were acquired using a
ﬂuorescence microscope. BX51 Olympus with a  20,  40 and  100 objective
with the analySIS image processing software (Olympus) or EVOS FL Color
Imaging System with a  40 and  60 objective.
Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate
nick-end labelling of lung sections. The lungs were ﬁxed in 4% buffered paraf-
ormaldehyde, pH 7.3, for 36 h and embedded in parafﬁn. Sections were depar-
afﬁnized, rehydrated and treated with 0.1M citrate buffer, pH 6.0, for 20min in a
water bath, washed and blocked in 0.1M Tris/HCl buffer, pH 7.5, supplemented
with 3% bovine serum albumin and 20% FCS. The slides were then incubated with
ﬂuorescein-coupled dUTP and TUNEL enzyme (Roche Diagnostics) in the pre-
sence of terminal deoxynucleotidyl transferase. The samples were then washed with
PBS, incubated for 10min at 70 C to remove unspeciﬁc binding. The sections were
mounted and analysed by ﬂuorescent microscopy using a  40 objective.
Autophagy. For autophagy on lung cells, 1 106 puriﬁed alveolar macrophages
were stimulated on glass slides in 24 multiwell plates with A. fumigatus live conidia
or P. aeuginosa and incubated for two at 37 C in 5% CO2. Cells were incubated
with 1:200 diluted anti-LC3 antibody (Cell Signaling Technology) overnight at
4 C in PBS containing 3% normal bovine serum albumin, incubated with
anti-rabbit–PE secondary antibody (Sigma-Aldrich), and ﬁxed for 20min in PBS
containing 4% paraformaldehyde. Images were acquired using the Olympus BX51
ﬂuorescence microscope with a  40 objective and analySIS image processing
software (Olympus). DAPI was used to detect nuclei. An equal amount of cell
lysate in 2 Laemmli buffer (Sigma-Aldrich) was probed with rabbit anti-LC3b-I
or anti-LC3b-II antibody (Abcam) for immunoblotting.
Proteasome assay. For studying proteasome activity, cells were plated on a 12-well
cell culture plate and stimulated with Aspergillus conidia in the presence of anakinra
for 4 h at 37 C. After incubation cells were lysed with NP-40 lysis buffer and the
amount of pmols of proteolytic activity was analysed with the proteasome activity
assay kit (Abcam) that takes advantage of the chymotrypsin-like activity, utilizing an
AMC-tagged peptide substrate (Proteasome Substrate (Succ-LLVY-AMC in DMSO)),
which releases free, highly ﬂuorescent AMC in the presence of proteolytic activity.
Conidiocidal activity. RAW264.7 cells were plated on 96-well cell culture plate in
supplemented RPMI medium. Cells were pretreatment for 30min with either
2.5 mM chloroquine (an acidophilic weak base that inhibits endosomal
acidiﬁcation), 5 mgml 1 brefeldin A (to inhibit the vacuolar pathway), 50 mM
lactacystin (to inhibit proteasomal degradation), 5mM 3-MA (to inhibit
autophagy), 2 mgml 1 DPI (to inhibit reactive oxygen species generation) and
50 mM rapamycin (to induce autophagy), exposed for 2 h to10 mgml 1 of
anakinra and stimulated with live A. fumigatus resting conidia for 2 h (10:1
cells/fungus ratio). Inhibition of CFUs (expressed as mean percentage±s.d.),
referred to as conidiocidal activity, was determined as described63.
Figure 8 | Anakinra inhibits inﬂammasome activation in human CF. (a) NLRP3 or NLRC4 staining of human bronchial epithelial (HBE) cells homozygous
for DF508 mutation and control cells exposed to P. aeruginosa or A. fumigatus conidia at cells:microbes ratio of 2:1, and/or 10mgml 1 of anakinra. Images
were acquired using the Olympus BX51 ﬂuorescence microscope with a 40 objective. Scale bar, 12.5 mm. DAPI was used to detect nuclei. Representative
images of two independent experiments from three patients. Histograms indicate per cent of human bronchial epithelial cells with positive NLRP3 or
NLRC4 expression. (b) IL-1b or (c) IL-1Ra in the supernatants of HBE cells from control or two CF patients exposed as above and (d) IL-1Ra levels in
expectorates from control or CF patients (ELISA). (e) NLRC4 expression by RT–PCR of CF patients carrying diverse genotypes at rs212704, rs455060,
rs7562653 and rs385076. (f) Best three-factor model. Dark grey and light grey boxes correspond to the high- and low-risk genotype combinations,
respectively. The left and right bars within each box correspond to Pseudomonasþ and Pseudomonas–, respectively. The top number above each bar is the
sum of scores for the corresponding group of individuals. The heights of the bars are proportional to the sum of scores in each group. Data pooled from two
experiments and presented as mean±s.d. for all bar graphs. *Po0.05, **Po0.01, ***Po0.001, treated versus untreated (none) (a,b) or control versus CF
patient (c,d), Two-way ANOVA (a–c) Bonferroni post hoc test and two-sides Student’s t-test (d).
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Human bronchial epithelial cells. HBE cells, homozygous for the DF508 muta-
tion and its isogenic wild type were obtained from lung transplants (CF patients) or
lung resections (non-CF patients) from and cultured as described46. Cells were
maintained at 37 C in a humidiﬁed incubator in an atmosphere containing 5%
CO2, and the experiments were done 5 days after plating. Cells were exposed to
A. fumigatus conidia or P. aeruginosa at cells:microbes ratio of 2:1, and treated
with 10 mgml 1 anakinra or vehicle. Cells were incubated for 4 h at 37 C in 5%
CO2 (as indicated by preliminary experiments). Cultures growing on culture
slides were ﬁxed for 20min in PBS containing 4% paraformaldehyde then
incubated with human anti-NLRP3 at 4 C in PBS containing 3% normal bovine
serum albumin, washed and incubated with anti-mouse-TRITC secondary
antibody (Sigma-Aldrich). Images were acquired using the Olympus BX51
ﬂuorescence microscope with a  40 objective and the analySIS image processing
software (Olympus). DAPI was used to detect nuclei.
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Reverse transcriptase-PCR and ELISA. The levels of cytokines in lung
homogenates and supernatants were determined by ELISAs (R&D Systems).
Real-time RT–PCR was performed using the BioRad CFX96 System and SYBR
Green chemistry (BioRad). Cells were lysed and total RNA was reverse transcribed
with cDNA Synthesis Kit (BioRad), according to the manufacturer’s instructions.
Ampliﬁcation efﬁciencies were validated and normalized against GAPDH. The
thermal proﬁle for SYBR Green real-time PCR was at 95 C for 3min, followed by 40
cycles of denaturation for 30 s at 95 C and an annealing/extension step of 30 s at
60 C. Each data point was examined for integrity by analysis of the ampliﬁcation
plot. The messenger RNA (mRNA)-normalized data were expressed as relative gene
mRNA in treated compared with untreated experimental groups or cells.
Western blotting. Blots of cell lysates were incubated with antibodies against the
following proteins: Caspase-1p10 (M-20 Cat. Number sc-514, Santa Cruz
Biotechnology), NLRP3 (Cat. Number ab4207, Abcam), NLRC4 (Cat. Number
06-1125, Millipore) and pNLRC4 (Genetech), LC3b-I or LC3b-II (Abcam) followed
by IgG–HRP-conjugated secondary antibody (Sigma–Aldrich) after separation in
12% Tris/glycine SDS gel and transfer to a nitrocellulose membrane. Normalization
was performed probing the membrane with mouse-anti-b-actin antibody
(Sigma–Aldrich). Chemiluminescence detection was performed with LiteAblotPlus
chemiluminescence substrate (Euroclone S.p.A), using the ChemiDocTM XRSþ
Imaging system (Bio-Rad), and quantiﬁcation was obtained by densitometry image
analysis using Image Lab 3.1.1 software (Bio-Rad). Images have been cropped for
presentation. Full size images are presented in Supplementary Figs 12-14.
Human studies
Patient data. A prospective multicenter longitudinal genetic association study
involving 284 patients of Caucasian origin who had a proven diagnosis of CF
(CFTR genotyping, sweat testing and clinical phenotype) was performed
(Supplementary Table 1). Clinical records from each patient were reviewed and
clinical data including age, gender, lung function testing, measures of nutrition,
microbiological ﬁndings and vital status were abstracted. A. fumigatus or
P. aeruginosa positivity was deﬁned as the presence of persistent positive Asper-
gillus cultures, but negative galactomannan and no immunological responses or
persistent, for at least 6 months, Pseudomonas, respectively.
SNPs selection and genotyping. Patients provided a blood specimen for DNA
isolation performed using the QIAamp DNA Mini (Qiagen, Milan, Italy) following
the manufacturer’s instructions and stored at  20 C. Supplementary Table 1
SNPs in NLRC4 and NLRP3 were selected based on their ability to tag surrounding
variants in the HapMap-CEU population of the International HapMap project,
NCBI build B36 assembly HapMap phase III (http://www.hapmap.org).
Haplotype-based tagging SNPs were selected by assessing LD blocks from the genes
of interest with a pairwise correlation coefﬁcient r2 of at least 0.80 and a minor
allele frequency higher than 5% in the HapMap-CEU population. In addition, the
rs1143627 SNP in IL1B and the 1,2 variable number of tandem repeats (VNTRs) in
Table 1 | Haplotype (a) and genotype (b)* association study between NLRC4 and Aspergillus infection; (c)w best models assessed
by the GMDR for one to ﬁve-way combinations, to test gene–gene interactions in determining Pseudomonas infection.
(a)
NLRC4Haplotypez NLRC4 SNPs Asp Aspþ OR P value
rs212704 rs455060 rs7562653 rs385076
H1 A T C C 122 (40.8%) 34 (47.6%) Reference
H2 G C T T 72 (24.1%) 20 (28.0%) 0.875 0.729
H3 G T C C 39 (13.1%) 8 (10.8%) 0.812 0.644
H4 G C C T 32 (10.7%) 1 (1.4%) 0.169 0.177
H5 G C C C 11 (3.8%) 1 (1.4%) 0.387 0.452
H6 A T T C 8 (2.7%) — 0.000 0.268
H7 A C T T 5 (1.7%) 4 (5.3%) 2.930 0.025
H8 A T T T 4 (1.4%) 1 (1.4%) 0.854 0.995
H9 A T C T 1 (0.4%) 1 (1.4%) 4.879 0.234
H10 G C T C — 1 (1.4%) 9.989eþ013 0.149
(b)
Status NLRC4 rs212704 A/G OR (P-value) G/G OR (P-value) Global P-value
A/A (%) A/G (%) G/G (%)
Asp 39 (22.9%) 83 (48.8%) 48 (28.2%) 0.996 (0.174) 0.303 (0.030) 0.071
Aspþ 9 (25.0%) 23 (63.9%) 4 (11.1%)
NLRC4 rs455060 C/T OR (P-value) T/T OR (P-value) Global P-value
Status C/C (%) C/T (%) T/T (%)
Asp 20 (12.2%) 90 (54.9%) 54 (32.9%) 0.750 (0.778) 0.774 (0.951) 0.881
Asp þ 6 (15.4%) 21 (53.9%) 12 (30.8%)
NLRC4 rs7562653 C/T OR (P-value) T/T OR (P-value) Global P-value
Status C/C (%) C/T (%) T/T (%)
Asp 83 (46.6%) 79 (44.4%) 16 (9.0%) 1.161 (0.691) 1.009 (0.900) 0.924
Asp þ 15 (37.5%) 21 (52.5%) 4 (10.0%)
NLRC4 rs385076 C/T OR (P-value) T/T OR (P-value) Global P-value
Status C/C (%) C/T (%) T/T (%)
Asp 61 (35.1%) 86 (49.4%) 27 (15.5%) 1.334 (0.260) 0.643 (0.274) 0.415
Asp þ 11 (28.2%) 24 (61.5%) 4 (10.3%)
(c)
Model TBA Sign Test (P) CVC OR (95% C.I.)
NLRC4 rs212704 0.516 6 (0.377) 9/10 2.150 (0.955-4.841)
NLRC4 rs212704 IL1RN VNTR 0.607 10 (0.001) 10/10 3.018 (1.464-6.219)
NLRC4 rs212704NLRC4 rs385076 IL1RN VNTR 0.612 10 (0.001) 10/10 4.212 (1.981-8.957)
NLRC4 rs212704NLRP3 rs10925026 x IL1RN VNTR IL1B rs1143627 0.530 7 (0.172) 6/10 6.024 (2.795-12.986)
NLRC4 rs212704NLRC4 rs7562653NLRP3 rs10925026 IL1RN VNTR IL1B rs1143627 0.519 6 (0.377) 9/10 12.622 (5.429-29.346)
SNP, single-nucleotide polymorphism; CVC, cross-validation consistency; TBA, testing balanced accuracy.
*Association tests were carried out using UNPHASED41 adjusting for sex and age at sampling. Signiﬁcant results are shown in bold.
wSigniﬁcant interaction models are shown in bold.
zGlobal haplotype test, P value¼0.092.
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IL1RN were also studied. SNP genotyping was performed by KASPar assays
(KBiosciences, Hertfordshire, UK) according to manufacturer’s instructions
using Applied Biosystems 7500 Fast qPCR system (Life Technologies, Milan, Italy).
The IL1RN VNTR polymorphism (86-bp repeat in intron 2) was analysed as
previously described66. The PCR products were analysed by 2% agarose gel
electrophoresis. Genotyping sets comprised randomly selected replicates of
previously typed samples and two negative controls (water). Concordant
genotyping was obtained for Z99%.
Statistical analysis. Data are expressed as mean±s.d. Horizontal bars indicate
the means. Statistical signiﬁcance was calculated by one or two-way ANOVA
(Bonferroni’s post hoc test) for multiple comparisons and by a two tailed Student’s
t-test for single comparison. Since the distribution of levels tested by
Kolmogorov–Smirnov normality test turned out to be non-signiﬁcant. We
considered all P values r0.05 signiﬁcant. The data reported are either
representative from three representative experiments (histology, immunoﬂuoresce,
TUNEL and western blotting) or pooled otherwise. The in vivo groups consisted of
4–6 mice per group. Data were analysed by GraphPad Prism 4.03 program
(GraphPad Software). No statistical method was used to predetermine sample size.
For human data, Hardy–Weinberg equilibrium (HWE) was tested using Haploview
v4.2. LD analysis was performed using Haploview, and deﬁning LD blocks based
on the solid spine of LD algorithm67. Case–control single marker and haplotype
association tests were performed using UNPHASED68 under an additive model
and adjusting for sex and age at sampling. Gene–gene interaction analyses were
performed with the Generalized-Multifactor Dimensionality Reduction method
(version 0.9)69. This method uses the same data-reduction strategy as the original
MDR method70, but score-based statistics using maximum-likelihood estimates are
introduced to classify multifactor cells into two different groups69. As in MDR, the
best n-locus model is selected based on the highest training accuracy, and the
maximum balanced testing accuracy and cross validation consistency are used to
determine the overall best epistasis model. Balanced testing accuracy is calculated
using the formula (sensitivityþ speciﬁcity)/2 to yield an unbiased estimate for
unbalanced case–control studies. Last, the w2 and sign tests determine whether the
factors are signiﬁcantly associated with the phenotype of interest. In particular, a
signiﬁcant w2-test reveals that the SNP or interaction between SNPs is associated
with phenotype tested, while a signiﬁcant sign test suggests that the best model
with one or more SNPs is signiﬁcantly better than the null model. Two-tail P values
are reported. Bonferroni’s correction for multiple testing was not performed since
we are assessing speciﬁc questions on genes involved in functional pathways related
to Pseudomonas and Aspergillus infection and we are not searching for associations
without a priori hypotheses71.
Study approval. Murine experiments were performed according to the Italian
Approved Animal Welfare Authorization 360/2015-PR and Legislative decree 26/
2014 regarding the animal licence obtained by the Italian Ministry of Health lasting
for ﬁve years (2015–2020). Infections were performed under avertin anaesthesia,
and all efforts were made to minimize suffering. Human studies approval was
obtained from institutional review boards at each site and written informed con-
sent was obtained from the participants, or, in case of minors, from parents or
guardian.
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